Agarwal PK - Search Results

1

Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer.

Fujisue Y, Azuma H, Inamoto T, Komura K, Agarwal PK, Masuda H, Watsuji T, Katsuoaka Y. Fujisue Y, et al. Among authors: agarwal pk. World J Urol. 2011 Oct;29(5):689-94. doi: 10.1007/s00345-010-0628-1. Epub 2010 Dec 16. World J Urol. 2011. PMID: 21161537

2

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

Oefelein MG, Agarwal PK, Resnick MI. Oefelein MG, et al. Among authors: agarwal pk. J Urol. 2004 Apr;171(4):1525-8. doi: 10.1097/01.ju.0000118294.88852.cd. J Urol. 2004. PMID: 15017212

3

Testosterone replacement therapy after primary treatment for prostate cancer.

Agarwal PK, Oefelein MG. Agarwal PK, et al. J Urol. 2005 Feb;173(2):533-6. doi: 10.1097/01.ju.0000143942.55896.64. J Urol. 2005. PMID: 15643240

4

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Agarwal PK, et al. Cancer. 2008 Jan 15;112(2):307-14. doi: 10.1002/cncr.23161. Cancer. 2008. PMID: 18050294 Free article.

5

Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.

Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Krane LS, et al. Among authors: agarwal pk. J Urol. 2010 Jan;183(1):118-24. doi: 10.1016/j.juro.2009.08.151. J Urol. 2010. PMID: 19913252

6

Editorial Comment.

Dahmen A, Agarwal PK, Modi PK. Dahmen A, et al. Among authors: agarwal pk. J Urol. 2024 Jun;211(6):750-751. doi: 10.1097/JU.0000000000003934. Epub 2024 May 9. J Urol. 2024. PMID: 38721935 No abstract available.

7

Testicular and paratesticular neoplasms in prepubertal males.

Agarwal PK, Palmer JS. Agarwal PK, et al. J Urol. 2006 Sep;176(3):875-81. doi: 10.1016/j.juro.2006.04.021. J Urol. 2006. PMID: 16890643 Review.

8

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Leibovici D, et al. Among authors: agarwal pk. Cancer. 2007 Jan 15;109(2):198-204. doi: 10.1002/cncr.22372. Cancer. 2007. PMID: 17171704 Free article.

9

Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.

Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Kassouf W, et al. Among authors: agarwal pk. Urology. 2009 Jan;73(1):147-52. doi: 10.1016/j.urology.2008.07.035. Epub 2008 Oct 9. Urology. 2009. PMID: 18848348 Free PMC article.

10

Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.

Krane LS, Menon M, Kaul SA, Siddiqui SA, Wambi C, Peabody JO, Agarwal PK. Krane LS, et al. Among authors: agarwal pk. Urol Oncol. 2011 Jul-Aug;29(4):372-7. doi: 10.1016/j.urolonc.2009.04.018. Epub 2009 Jul 3. Urol Oncol. 2011. PMID: 19576796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

429 results

Search Page

Filters